Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · IEX Real-Time Price · USD
1.160
+0.060 (5.45%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Ginkgo Bioworks Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
251.46477.71313.8476.6654.18
Revenue Growth (YoY)
-47.36%52.21%309.40%41.48%-
Cost of Revenue
54.01204.22129.6915.610
Gross Profit
197.45273.49184.1561.0554.18
Selling, General & Admin
385.031,430862.9538.3129.48
Research & Development
580.621,0531,150159.7796.3
Other Operating Expenses
96.210000
Operating Expenses
1,0622,4822,013198.07125.78
Operating Income
-864.41-2,208.95-1,828.47-137.03-71.6
Interest Expense / Income
0.090.112.372.392.42
Other Expense / Income
28.44-89.10.69-14.6945.29
Pretax Income
-892.94-2,119.96-1,831.53-124.72-119.31
Income Tax
-0.07-15.03-1.481.890.02
Net Income
-892.87-2,104.93-1,830.05-126.61-119.33
Shares Outstanding (Basic)
1,9441,6791,3601,2751,149
Shares Outstanding (Diluted)
1,9441,6801,3601,2751,149
Shares Change
15.75%23.48%6.72%10.95%-
EPS (Basic)
-0.46-1.25-1.35-0.10-0.10
EPS (Diluted)
-0.46-1.25-1.39-0.10-0.10
Free Cash Flow
-331.87-304.47-310.34-193.65-66.88
Free Cash Flow Per Share
-0.17-0.18-0.23-0.15-0.06
Gross Margin
78.52%57.25%58.68%79.64%100.00%
Operating Margin
-343.76%-462.41%-582.62%-178.75%-132.14%
Profit Margin
-355.08%-440.63%-583.12%-165.16%-220.23%
Free Cash Flow Margin
-131.98%-63.74%-98.89%-252.62%-123.43%
EBITDA
-792.98-2,056.35-1,800.08-108.47-106.13
EBITDA Margin
-315.36%-430.46%-573.57%-141.50%-195.87%
Depreciation & Amortization
99.8763.5129.0813.8610.76
EBIT
-892.85-2,119.85-1,829.15-122.34-116.88
EBIT Margin
-355.07%-443.76%-582.84%-159.59%-215.72%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).